EUCTR2009-017026-39-NL进行中（未招募）不适用
A PHASE III TRIAL OF ALD-101 ADUVANT THERAPY of UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION (UCBT) IN PATIENTS WITH INBORN ERRORS OF METABOLISM
Aldagen, Inc0 个研究点目标入组 40 人开始时间: 2009年10月29日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Patients must have a confirmed diagnosis of inborn error of metabolism. Diagnosis to be confirmed by two appropriate tests (enzyme or mutation analysis) before study entry.
- •Inborn errors of metabolism include the following:
- •Hurler Syndrome (MPS I)
- •Hurler-Scheie Syndrome
- •Hunter Syndrome (MPS II)
- •Sanfilippo Syndrome (MPS III)
- •Maroteau-Lamy Syndrome (MPS VI)
- •Krabbe Disease (Globoid Leukodystrophy)
- •Metachromatic Leukodystrophy (MLD)
- •Adrenoleukodystrophy ALD and AMN)
- •Sandhoff Disease
- •Tay Sachs Disease
- •Pelizaeus Merzbacher (PMD)
- •Neiman-Pick Disease
- •Alpha-mannosidosis
- •I-Cell Disease (ML II)
- •Fucosidosis
- •GM1 Gangliosidosis
- •Canavan Disease
- •2. Patients must be <16 years of age at the time of study enrollment.
- •3. Patients must be = 5 kg in weight.
- •4. Patients must have a good performance status (Lansky =80%).
- •5. Patients must have adequate function of other organ systems as measured by:
- •Creatinine < 2.0 mg/dl and creatinine clearance > 60 cc/min/1.73m2. Newborns must have a creatinine clearance > 25 cc/min. For babies < 3 months of age, the raw value on GFR must be > 1 cc/kg/min.
- •Hepatic transaminases (ALT/AST) <4 x normal, bilirubin <2.0mg/dl
- •Cardiac function by echocardiogram or radionuclide scan (ejection fraction or shortening fraction >80% of normal value for age)
- •Pulmonary function tests demonstrating FVC, CVC or FEV1 of >60% of predicted for age. If child is too young for PFTs, the option of crying vial capacity (CVC) testing is recommended. If CVC is not available at the investigational site, a room air pulse oxymetry oxygen = 94% will be required to meet entry criteria.
- •6. Patient, and parent, or legal guardian must have given written informed consent according to FDA guidelines.
- •7. Patients must have a minimum life expectancy of at least 6 months.
- •8. Patient must be determined to be a good candidate for a standard UCBT according to the investigator and standard eligibility work-up at the site.
- •9. Patients must have an IQ >70 or if too young for IQ testing the potential to reach this endpoint by age 5.
- •10. Patient must have an available 4, 5, or 6/6 antigen matching unrelated UCB unit cryopreserved in a compartmentalized bag that will deliver a cell dose between =2.5 x 10e7cells/kg from one fraction (based on the precryopreservation cell content). The cord blood unit must be stored in a dual compartment bag or 2 bags to enable manufacturing ALD-101 prior to conventional transplantation.
- •11. Female patients of childbearing potential cannot be pregnant or lactating/breast-feeding and must be either surgically sterile, no menses for the previous 12 months, or must be practicing an effective method of birth control as determined by the investigator (e.g., oral contraceptives, double barrier methods, hormonal injectable or implanted contraceptives, tubal ligation, or partner with existing vasectomy).
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Patients that are HIV, Hepatitis B and/or Hepatitis C positive.
- •2. Patients that are concurrently involved in any other clinical study that affects engraftment or immune reconstitution (e.g., other hematopoietic growth factors).
- •3. Patients with uncontrolled seizures, apnea, evidence of aspiration pneumonia, or evidence of brain stem involvement on MRI scans.
- •4. Patients with uncontrolled infections.
- •5. Patients with prior allogeneic stem cell transplant with cytoreduction preparative therapy within 12 months of enrollment.
- •6. Patients that have any comorbid condition which, in the view of the Principal Investigators, renders the patient at too high a risk from treatment complications and regimen related morbidity/mortality.
研究者
相似试验
进行中（未招募）
不适用
A PHASE III TRIAL OF ALD-101 ADUVANT THERAPY of UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION (UCBT) IN PATIENTS WITH INBORN ERRORS OF METABOLISMMedDRA version: 9.1Level: LLTClassification code 10062018Term: Inborn error of metabolismInborn errors of metabolismEUCTR2009-011921-15-NLAldagen, Inc40
已完成
3 期
A PHASE III TRIAL OF ALD-101 ADUVANT THERAPY of UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION (UCBT) IN PATIENTS WITH INBORN ERRORS OF METABOLISMinborn errors of metabolismNL-OMON32439Aldagen, Inc.12
进行中（未招募）
3 期
AYD001 Phase III Clinical TrialPatients with chronic renal failure undergoing hemodialysisJPRN-jRCT2031210570Asaoka Kuniharu60
进行中（未招募）
1 期
Treatment with chemotherapy for children >1 and <19 years of age with acute lymphoblastic leukemia.Acute lymphoblastic leukemia in childrenMedDRA version: 21.0Level: LLTClassification code 10000845Term: Acute lymphoblastic leukemiaSystem Organ Class: 100000004864EUCTR2012-000067-25-NLPrincess Máxima Center for pediatric oncology819
未知
3 期
Phase 3 Clinical Trial with MD-0901JPRN-jRCT2080222425MOCHIDA PHARMACEUTICAL CO., LTD.250